A combination of a personalized vaccine and an immunotherapy drug leads to the reduction of advanced liver cancer in small trial.A third of patients with advanced liver cancer who received a personalized vaccine in a small trial saw tumors shrink. Geneos Therapeutics has announced the publication of positive safety, immunogenicity, and efficacy data in. It is also a leading cause of cancer-related death worldwide. Only in the United States, it is responsible for overdeaths per year.
As explained, researchers used samples from patients’ tumors to build vaccines based on new mutations present in an individual patient’s tumor. Liver cancer contains fewer mutations, which leads to diminished efficacy of immunotherapies. The results suggest that vaccines based on mutations only present in a patient’s tumor may boost the immune system. It does in a way that improves the ability to recognize and attack cancers.
This Geneos treatment is a DNA vaccine that delivers the genetic code of mutated proteins into cells through a small electrical impulse. Each vaccine can target up to 40 mutated genes.